UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Étude multicentrique cas témoins de l’efficacité en vie réelle de l’association chimiothérapie immunothérapie dans les cancers bronchiques à petites cellules disséminés

Revue des maladies respiratoires actualités, 2023-01, Vol.15 (1), p.32

2023

Volltextzugriff (PDF)

Nivolumab-induced Organizing pneumonitis in a patient with lung sarcomatoid carcinoma

Lung cancer (Amsterdam, Netherlands), 2016-09, Vol.99, p.162-165

2016

Volltextzugriff (PDF)

Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts)

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Volltextzugriff (PDF)

Irradiation prophylactique des orifices de drainage dans le mésothéliome pleural : un essai de phase 3, « SMART » mais pas trop

Revue des maladies respiratoires, 2016-10, Vol.33 (8), p.654-657

2016

Volltextzugriff (PDF)

Prophylactic radiotherapy for procedure-tracts metastases in pleural mesothelioma: A phase 3 trial, "SMART"… not enough

Revue des maladies respiratoires, 2016-10, Vol.33 (8), p.654

2016

Volltextzugriff (PDF)

Role of immunotherapy in locally advanced non-small cell lung cancer

Cancer radiothérapie, 2020-02, Vol.24 (1), p.67

2020

Volltextzugriff (PDF)

Traitements péri-opératoires des carcinomes bronchiques non à petites cellules

Revue des maladies respiratoires, 2017-06, Vol.34 (6), p.618-634

2017

Volltextzugriff (PDF)

Place de l’immunothérapie dans le cancer bronchique non à petites cellules localement avancé

Cancer radiothérapie, 2020-02, Vol.24 (1), p.67-72

2020

Volltextzugriff (PDF)

Antiangiogéniques en cancérologie thoracique : critères de prescription et gestion des effets indésirables

Revue des maladies respiratoires actualités, 2015-11, Vol.7 (4), p.414-422

2015

Volltextzugriff (PDF)

Role of immunotherapy in locally advanced non-small cell lung cancer

Cancer radiothérapie, 2020-02, Vol.24 (1), p.67-72

2020

Volltextzugriff (PDF)

Current knowledge on perioperative treatments of non-small cell lung carcinomas

Revue des maladies respiratoires, 2017-06, Vol.34 (6), p.618

2017

Volltextzugriff (PDF)

1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

Annals of oncology, 2024-09, Vol.35, p.S842-S842

2024

Volltextzugriff (PDF)

1307P Clinical characteristics and therapeutic sequences of KRAS G12C advanced non-small cell lung cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA)

Annals of oncology, 2024-09, Vol.35, p.S831-S832

2024

Volltextzugriff (PDF)

941P PET-derived parameters for response assessment in neoadjuvant atezolizumab: A secondary analysis of PRINCEPS phase II trial

Annals of oncology, 2022-09, Vol.33, p.S977-S978

2022

Volltextzugriff (PDF)

1735P Circulating T-cell immunosenescence in patients with thymic epithelial tumors (TETs)

Annals of oncology, 2021-09, Vol.32, p.S1200-S1201

2021

Volltextzugriff (PDF)

Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial

European journal of cancer (1990), 2022-10, Vol.174, p.S82-S82

2022

Volltextzugriff (PDF)

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

Cancer management and research, 2021-01, Vol.13, p.2805-2810

2021

Volltextzugriff (PDF)

1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy

Annals of oncology, 2021-09, Vol.32, p.S991-S991

2021

Volltextzugriff (PDF)

1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC

Annals of oncology, 2021-09, Vol.32, p.S1004-S1004

2021

Volltextzugriff (PDF)

1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC)

Annals of oncology, 2021-09, Vol.32, p.S1024-S1025

2021

Volltextzugriff (PDF)

1198P Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)

Annals of oncology, 2021-09, Vol.32, p.S956-S957

2021

Volltextzugriff (PDF)

P1.16-02 Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S127

2022

Volltextzugriff (PDF)

22P Clinical utility of ddPCR for detection of sensitizing and resistance EGFRm in pts with advanced NSCLC

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S707-S708

2021

Volltextzugriff (PDF)

P34.06 The Clinical Utility of Liquid Biopsy by Digital Droplet PCR in Patients with Advanced NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S417-S417

2021

Volltextzugriff (PDF)

P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S409-S409

2021

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(45)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Humans
(7)
Life Sciences
(6)
Lung Cancer
(6)
Oncology
(5)
Cancer
(4)
Radiotherapy
(4)
Aged
(3)
Female
(3)
Male
(3)
Respiratory System
(3)
Adult
(2)
Antibodies, Monoclonal - Therapeutic Use
(2)
Antineoplastic Agents, Immunological - Adverse Effects
(2)
Antineoplastic Agents, Immunological - Therapeutic Use
(2)
Cancer Du Poumon
(2)
Carcinoma, Non-Small-Cell Lung - Therapy
(2)
Central Nervous System
(2)
Chemotherapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Étude multicentrique cas témoins de l’efficacité en vie réelle de l’association chimiothérapie immunothérapie dans les cancers bronchiques à petites cellules disséminés

Nivolumab-induced Organizing pneumonitis in a patient with lung sarcomatoid carcinoma

Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts)

Irradiation prophylactique des orifices de drainage dans le mésothéliome pleural : un essai de phase 3, « SMART » mais pas trop

Prophylactic radiotherapy for procedure-tracts metastases in pleural mesothelioma: A phase 3 trial, "SMART"… not enough

Role of immunotherapy in locally advanced non-small cell lung cancer

Traitements péri-opératoires des carcinomes bronchiques non à petites cellules

Place de l’immunothérapie dans le cancer bronchique non à petites cellules localement avancé

Antiangiogéniques en cancérologie thoracique : critères de prescription et gestion des effets indésirables

Role of immunotherapy in locally advanced non-small cell lung cancer

Current knowledge on perioperative treatments of non-small cell lung carcinomas

1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

1307P Clinical characteristics and therapeutic sequences of KRAS G12C advanced non-small cell lung cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA)

941P PET-derived parameters for response assessment in neoadjuvant atezolizumab: A secondary analysis of PRINCEPS phase II trial

1735P Circulating T-cell immunosenescence in patients with thymic epithelial tumors (TETs)

Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy

1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC

1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC)

1198P Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)

P1.16-02 Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale

22P Clinical utility of ddPCR for detection of sensitizing and resistance EGFRm in pts with advanced NSCLC

P34.06 The Clinical Utility of Liquid Biopsy by Digital Droplet PCR in Patients with Advanced NSCLC

P33.10 Identification of Long-Responders and Fast-Progressors under Immunotherapy Based on Early Monitoring of dNLR in Advanced NSCLC Patients

Suchergebnisse filtern